Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the future of biosimilars in oncology.
Martina Weise, MD
Advertisement
Articles by Martina Weise, MD
Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the value of biosimilars in oncology.
Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.
Advertisement
Latest Updated Articles
Dr. Weise Discusses the Value of Biosimilars in OncologyOctober 31st 2018
Dr. Weise Discusses the Future of Biosimilars in OncologyNovember 9th 2018
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5